BioSig Tech. (BSGM) & Electrophysiology Sector - BioSig Technologies, Inc. Issues Shareholder Letter with Corporate Update on Recent Achievements - BioSig Tech. (BSGM) & Electrophysiology Sector - InvestorVillage


BioSig Tech. (BSGM) & Electrophysiology Sector (related stock BSGM)
This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: BioSig Tech. (BSGM) & Electrophysiology Sector   /  Message Board  /  Read Message

 
 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  2316 of 2333  at  5/11/2022 8:34:49 AM  by

ZombieInvestor


BioSig Technologies, Inc. Issues Shareholder Letter with Corporate Update on Recent Achievements

Recent Company highlights include:

The growth of its PURE EP(TM) System from its first-in-human surgical procedures in 2019 to completing over 2,200 patient cases with 75 physicians at 17 hospitals across the United States.

BioSig strengthened its management with a new commercialization team led by industry veteran Gray Fleming, Chief Commercial Officer, who spent 18 years with St. Jude Medical.

The rollout of a two-phase approach for purchase, lease, or rental options for PURE EP and a new go-to-market strategy for commercialization.

Launch of its new NOVA-5 software at the Heart Rhythm Society Convention on April 29, 2022. NOVA-5 offers greater customization and smarter workflows with the aim of further driving clinical adoption.

Recapped the successful completion of its first blinded clinical trial in 2021 and published those results in a leading peer-reviewed journal. Titled "Evaluation of a novel cardiac signal processing system for electrophysiology procedures: The PURE EP 2.0 study," the study was conducted at three leading medical centers across the United States: St. David's Medical Center (TCAI), Mayo Clinic, and Massachusetts General Hospital.

A snapshot into Biosig's financing included no debt and positioning in a global electrophysiology device market which, according to Grand View Research, could reach $12.2 billion by 2026 and expand at a growth rate of approximately 12%.

https://finance.yahoo.com/news/biosig-technologies-inc-issues-shareholder-123000848.html


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 5  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board


Financial Market Data provided by
.
Loading...